ADMA Biologics Inc (ADMA)

Currency in USD
17.0500
-0.0800(-0.47%)
Closed·
After Hours
16.7700-0.2800(-1.64%)
·

ADMA Financial Summary

Key Ratios

P/E Ratio23.91
Price/Book12.76
Debt / Equity21.96%
Return on Equity78.45%
Dividend Yield0.00%
EBITDA147.03M
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2015
31/12
2016
31/12
2017
31/12
2018
31/12
2019
31/12
2020
31/12
2021
31/12
2022
31/12
2023
31/12
2024
31/12
* In Millions of USD (except for per share items)

Analyst Ratings

2 Buy
1 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 29.4900
(+72.96% Upside)

Earnings

Latest Release
May 07, 2025
EPS / Forecast
0.1361 / 0.1467
Revenue / Forecast
114.80M / 112.97M
EPS Revisions
Last 90 days

FAQ

What were ADMA Biologics Inc's earnings for the latest quarter?

The ADMA Biologics Inc EPS (TTM) is 0.88. ADMA Biologics Inc reported sales of 114.80, net income of 26.90, and EPS of 0.14 for the latest quarter.

What was ADMA Biologics Inc's net income for the latest quarter?

ADMA Biologics Inc's net income for the latest quarter was 26.90.

How did ADMA Biologics Inc's performance compare year-over-year in the latest quarter?

The company's revenue moved from 117.55 in the previous quarter to 114.80 in the latest quarter, and net income moved from 111.90 to 26.90 compared to the previous quarter.

What is ADMA Biologics Inc's net profit margin on a TTM basis?

ADMA Biologics Inc's trailing twelve months (TTM) net profit margin is 46.35%.

How does ADMA Biologics Inc's debt to equity ratio compare to industry standards?

ADMA Biologics Inc's total debt-to-equity ratio is 21.96%.

What is ADMA Biologics Inc's return on investment on a TTM basis?

ADMA Biologics Inc's trailing twelve months (TTM) return on investment (ROI) is 78.45%.

Did ADMA Biologics Inc gain or lose cash last quarter?

In the latest quarter, ADMA Biologics Inc's net change in cash was -31.52 million.

What were ADMA Biologics Inc's total assets and liabilities in the latest quarter?

As of the latest quarter, ADMA Biologics Inc reported total assets of 510.57 million and total liabilities of 53.50 million.

How has ADMA Biologics Inc's total revenue grown this year?

ADMA Biologics Inc's total revenue was 117.55 in the previous quarter and 114.80 in the latest quarter.

What is ADMA Biologics Inc's gross margin on a TTM basis?

ADMA Biologics Inc's trailing twelve months (TTM) gross margin is 52.58%.

What was ADMA Biologics Inc's revenue per share for the latest quarter?

ADMA Biologics Inc's revenue per share for the latest quarter was 43.97.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.